Clinical studies examining the impact of obesity on breast cancer risk and prognosis

Journal of Mammary Gland Biology and Neoplasia

Volumn 18, Issue 3-4, 2013, Pages 257-266

  Jain, Rishi ^a   Strickler, Howard D ^a   Fine, Eugene ^a   Sparano, Joseph A ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Body mass index; Breast cancer; Obesity; Prognosis; Recurrence

Indexed keywords

ANASTROZOLE; DOXORUBICIN; INSULIN; LETROZOLE; METFORMIN; SOMATOMEDIN; TAMOXIFEN; TRASTUZUMAB;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARBOHYDRATE INTAKE; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; EXERCISE; FAT INTAKE; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIFESTYLE; METASTASIS; MONOTHERAPY; OBESITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; SECOND CANCER; TRIPLE NEGATIVE BREAST CANCER; WEIGHT GAIN;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OBESITY; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS;

EID: 84890120128     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-013-9307-3     Document Type: Article

References (68)

1. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.
2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-91.
3. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-41.
4. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012:1-8.
5. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013;105:1344-54.
6. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
7. Pollack A. A.M.A. Recognizes Obesity as a Disease. New York times, June 18. 2013.
8. Cheraghi Z, Poorolajal J, Hashem T, et al. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7:e51446.
9. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
10. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-35.
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
12. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101:48-60.
13. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk [see comments]. JAMA. 1997;278:1407-11.
14. Kerlikowske K, Walker R, Miglioretti DL, et al. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008;100:1724-33.
15. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control. 2006;17:695-703.
16. Suzuki R, Iwasaki M, Inoue M, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer. 2011;129:1214-24.
17. Pierobon MFC. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307-14.
18. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-35
19. Kamineni A, Anderson ML, White E, et al. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control. 2013;24:305-12.
20. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013.
21. Griggs JJSM, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-73.
22. Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14:3000-8.
23. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
24. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat. 2002;74:65-76.
25. Subbaramaiah K, Morris PG, Zhou XK, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2:356-65.
26. Folkerd EJ, Dixon JM, Renshaw L, et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30:2977-80.
27. Majed BMT, Senouci K, et al. Is obesity an independent prognosis factor in women breast cancer. Breast Cancer Res Treat. 2008;111:329-42.
28. Sparano JAWM, Zhar F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118:5937-46.
29. Ligibel JACC, Liu MC, et al. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Aliance). J Clin Oncol. 2013;31:57s.
30. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160-7.
31. Lakhani AGR, Duan X, et al. Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer. Cancer Res. 2012;72:144s.
32. Pollan MPB, Martin M, et al. The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes. J Clin Oncol. 2013;31:56s.
33. Azambuja EDM-SW, Francis P, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy:the experience of the BIG 02-98 trial. Breast Cancer Res Treat. 2010;119:145-53.
34. Dawood SLX, Litton JK. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clinical Breast Cancer. 2012;12:364-72.
35. Crozier JA, Moreno-Aspitia A, Ballman KV, et al. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013;119:2447-54.
36. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clini Oncol. 2010;28:3784-96.
37. Sestak IDW, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trail. J Clin Oncol. 2010;28:3411-5.
38. Ewertz MGK, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 Trial. J Clin Oncol. 2012;30:3967-75.
39. Pfeiler GKR, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653-9.
40. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751-7.
41. Jonat W, Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest. 2007;25:14-8.
42. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2012;17:251-61.
43. Col NFOL, Springmann V, et al. Metformin and breast cancer risk. Breast Cancer Res Treat. 2012;135:639-46.
44. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial. J Clin Oncol. 2013;31:1398-404.
45. Goodwin PJSV. Obesity and insulin resistance in breast cancer - chemoprevention strategies with a focus on metformin. Breast. 2011;S3:S31-5.
46. Goodwin PJ, Stambolic V, Lemieux J, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-20
47. Goodwin PJ PW, Gelmon KA, et al. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol. 2013;31:57s.
48. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30:2593-600.
49. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-41.
50. Ligibel JA, Strickler HD. Obesity and its impact on breast cancer. Am Soc Clin Oncol Educ Book. 2013;2013:52-9.
51. Chlebowski RTBG, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767-76.
52. Chlebowski R, Blackburn GL, Thomson C. Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome, American Society of Clinical Oncology. J Clin Oncol. 2008:Abst 522
53. Segal R, Pond G, Vallis M. Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. J Clin Oncol. 2011;29:abstr 512.
54. Pierce JPNL, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, fiber and low in fat on prognosis following treatment for breast cancer; the Women's Healthy Eating and Living (WHEL) randomized trial. J Am Medical Assoc. 2007;298:289-98.
55. Gannon MC, Nuttall FQ. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes. 2004;53:2375-82.
56. Hernandez TL, Sutherland JP, Wolfe P, et al. Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am J Clin Nutr. 2010;91:578-85.
57. Hwalla N, Shaker L, Torbay N, et al. Postprandial glycemic and insulinemic responses to high-carbohydrate vs high-protein meals in obese normoglycemic subjects with varied insulin sensitivity. Nutr Res. 2005;25:535-48.
58. Nuttall FQ, Gannon MC, Saeed A, et al. The metabolic response of subjects with type 2 diabetes to a high-protein, weight-maintenance diet. J Clin Endocrinol Metab. 2003;88:3577-83.
59. Meckling KA, O'Sullivan C, Saari D. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. J Clin Endocrinol Metab. 2004;89:2717-23.
60. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778-85.
61. Fraser DA, Thoen J, Bondhus S, et al. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients. Clin Exp Rheumatol. 2000;18:209-14.
62. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:s836-42.
63. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord. 2002;26:747-53.
64. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
65. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010;153:147-57.
66. Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28:1028-35.
67. Chlebowski R BG, Thomson C. Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. J Clin Oncol. 2008:26.
68. Segal R PG, Vallis M. Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. J Clin Oncol. 2011;29.